XORTX Therapeutics (XRTX) Change in Intangibles (2020 - 2026)
XORTX Therapeutics' (XRTX) quarterly Change in Intangibles came in at -$3788.0 in Q1 2026, down 11.91% YoY from -$4299.9 in Q1 2025, and up 84.56% on a QoQ basis from -$24527.0 in Q4 2025.
XORTX Therapeutics (XRTX) Change in Intangibles (2020 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 7 years of Change in Intangibles data on file, last reported at -$3788.0 in Q1 2026.
- Quarterly Change in Intangibles fell 11.91% year-over-year to -$3788.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$55626.0 (down 245.76% YoY) and the FY2025 annual result came in at -$55223.0, down 241.87% from the prior year.
- Change in Intangibles grew to -$3788.0 in Q1 2026, from -$24527.0 in the prior quarter.
- In the past five years, Change in Intangibles ranged from a high of $74310.0 in Q4 2023 to a low of -$24527.0 in Q4 2025.
- A 5-year average of -$238.32 and a median of -$6860.6 in 2022 frame the typical range for Change in Intangibles.
- Annual changes were most pronounced in 2022 — Change in Intangibles plunged 1695.36% — and 2023, when it soared 752.32%.
- Tracing XRTX's Change in Intangibles over 5 years: stood at -$11391.6 in 2022, then soared by 752.32% to $74310.0 in 2023, then decreased by 0.67% to $73812.0 in 2024, then plunged by 133.23% to -$24527.0 in 2025, then soared by 84.56% to -$3788.0 in 2026.
- The last three Change in Intangibles figures came in at -$3788.0 (Q1 2026), -$24527.0 (Q4 2025), and -$5486.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.68 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - | -3,788.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,788.00 |
| Mar 31, 2026 | -3,788.00 |
| Dec 31, 2025 | -24,527.00 |
| Dec 31, 2025 | -24,527.00 |
| Sep 30, 2025 | -5,486.00 |
| Sep 30, 2025 | -5,486.00 |
| Jun 30, 2025 | -21,825.00 |
| Jun 30, 2025 | -21,825.00 |
| Mar 31, 2025 | -3,385.00 |
| Mar 31, 2025 | -3,385.00 |
| Dec 31, 2024 | 73,812.00 |
| Dec 31, 2024 | 73,812.00 |
| Sep 30, 2024 | -23,181.00 |
| Sep 30, 2024 | -23,181.00 |
| Jun 30, 2024 | -9,084.00 |
| Jun 30, 2024 | -9,084.00 |
| Mar 31, 2024 | -2,623.00 |
| Mar 31, 2024 | -2,623.00 |
| Dec 31, 2023 | 74,310.00 |
| Dec 31, 2023 | 74,310.00 |